We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urinary Detection Method Developed for Prostate Cancer

By LabMedica International staff writers
Posted on 22 Jan 2019
Prostate cancer (PCa) is one of the most common types of malignancy worldwide and is the second leading cause of cancer death among men. More...
This cancer tends to be asymptomatic and slow growing, often with onset in young men, but usually not detected until the age of 40 to 50 years.

The conventional methods for PCa screening recommended by the American Cancer Society are serum prostate specific antigen (PSA) testing and digital rectal examination (DRE). However, these methods have some drawbacks due to their sensitivity, specificity and accuracy. The PCA3 gene has shown promise as a non-invasive PCa biomarker.

Scientists at Mahidol University (Bangkok, Thailand) collected spot urine samples from five healthy male volunteers, first voided post-DRE urine from five benign prostate hyperplasia (BPH) patients and from five PCa patients. Diagnosis of patients was made by histopathological analysis after prostate biopsy subsequently. PCa patients were identified with positive biopsy.

Total RNA was isolated from the cell pellets of urine as well as from cell lines and total RNA was converted to cDNA using RevertAid First Strand cDNA synthesis kit. The team developed an assay based on interactions between unmodified gold nanoparticles (AuNPs) and thiolated polymerase chain reaction (PCR) products. Thiolated PCR products were amplified by RT-PCR using a thiol-labeled primer at the 5′ end. Thiolated products of PCA3 bound to the surface of AuNPs and led to the prevention of salt-induced aggregation (red color). In the absence of the PCR products, AuNPs changed their color from red to blue due to the salt-induced aggregation. These changes were detected by the naked eye and a microplate spectrophotometer.

The team reported that assay was specific for PCA3 in prostate cancer cell lines with a visual detection limit of 31.25 ng/reaction. The absorption ratio 520/640 nm was linear against PCR product concentration in the reaction. This method is promising for discrimination of prostate cancer patients from both healthy controls and benign prostatic hyperplasia patients according to their urinary PCA3 expression levels. The results indicated that the proposed colorimetric assay was more sensitive than gel electrophoresis.

The authors concluded that a sensitive and specific AuNP-based colorimetric method for visual detection of PCA3 in prostate cancer was successfully developed. This new method was based on interactions between thiolated PCR products and unmodified AuNPs. The positive and negative results were clearly distinguished by the naked eye, being red and blue color, respectively. The incubation time was short and results were obtained within 10 minutes of RT-PCR completion. Moreover, a large number of samples could be tested simultaneously in 96-well microtiter plates. The study was published in the January 2019 issue of the journal Clinica Chimica Acta.

Related Links:
Mahidol University


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.